{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"Major and clinically relevant non-major bleeding. Using the ISTH classification, bleeding is defined as major if it is overt and associated with a decrease in the hemoglobin level of 2 g/dL or more, requires the transfusion of 2 or more units of blood, occurs into a critical site, or contributes to death (12).\n\nUsing the ISTH classification, clinically relevant nonmajor bleeding is defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, surgical intervention, or interruption of the study drug.","groups":[{"description":"apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months\n\nApixaban: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months","id":"OG000","title":"Apixaban"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6 months","title":"Frequency of Major and Clinically Relevant Non-major Bleeding","type":"PRIMARY","unitOfMeasure":"Participants"}